MYC and acute myeloid leukemia: MYB and its target SKI (a transforming growth factor β signaling inhibitor) were responsible for the inhibition of AML differentiation, and the treatment of MYC-driven HL-60 and U937 AML cells with valproic acid or panobinostat suppressed the levels of MYB and SKI[193].